Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Pulmonx Corporation

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Pulmonx, with a price target of $3.00. The company’s s...

Wells Fargo Sticks to Their Hold Rating for Pulmonx (LUNG)

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Pulmonx today and set a price target of $5.00. Wise covers the Healthcare sector, focu...

Stifel Nicolaus Sticks to Their Buy Rating for Pulmonx (LUNG)

In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Pulmonx, with a price target of $2.50. According to TipRank...

Piper Sandler Sticks to Its Hold Rating for Pulmonx (LUNG)

Pulmonx Corporation ( ($LUNG) ) has released its Q3 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its investors...

Pulmonx Corporation Reports Q3 2025 Financial Results

In a report released yesterday, John Young CFA from Canaccord Genuity maintained a Buy rating on Pulmonx, with a price target of $6.00. The company...

Canaccord Genuity Remains a Buy on Pulmonx (LUNG)

In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Pulmonx, with a price target of $2.50. The company’s shares...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LUNG	$1.44	+9.92%	756.38K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LUNG	$1.44	+9.9%	756.38K
3
4
5
6

LUNG

LUNG

Get Pulmonx Corporation Data in Excel

Get Pulmonx Corporation Data in Excel